GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biovica International AB (OSTO:BIOVIC B) » Definitions » EV-to-Revenue

Biovica International AB (OSTO:BIOVIC B) EV-to-Revenue : 8.45 (As of May. 26, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Biovica International AB EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Biovica International AB's enterprise value is kr53.61 Mil. Biovica International AB's Revenue for the trailing twelve months (TTM) ended in Jan. 2024 was kr6.34 Mil. Therefore, Biovica International AB's EV-to-Revenue for today is 8.45.

The historical rank and industry rank for Biovica International AB's EV-to-Revenue or its related term are showing as below:

OSTO:BIOVIC B' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.55   Med: 96.62   Max: 3219.09
Current: 8.46

During the past 9 years, the highest EV-to-Revenue of Biovica International AB was 3219.09. The lowest was 0.55. And the median was 96.62.

OSTO:BIOVIC B's EV-to-Revenue is ranked worse than
50.63% of 1039 companies
in the Biotechnology industry
Industry Median: 8.18 vs OSTO:BIOVIC B: 8.46

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-26), Biovica International AB's stock price is kr1.792. Biovica International AB's Revenue per Share for the trailing twelve months (TTM) ended in Jan. 2024 was kr0.13. Therefore, Biovica International AB's PS Ratio for today is 13.47.


Biovica International AB EV-to-Revenue Historical Data

The historical data trend for Biovica International AB's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biovica International AB EV-to-Revenue Chart

Biovica International AB Annual Data
Trend Apr15 Apr16 Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only 59.02 196.33 485.21 405.57 67.17

Biovica International AB Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 78.09 67.17 70.01 12.28 19.16

Competitive Comparison of Biovica International AB's EV-to-Revenue

For the Biotechnology subindustry, Biovica International AB's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biovica International AB's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biovica International AB's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Biovica International AB's EV-to-Revenue falls into.



Biovica International AB EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Biovica International AB's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=53.608/6.344
=8.45

Biovica International AB's current Enterprise Value is kr53.61 Mil.
Biovica International AB's Revenue for the trailing twelve months (TTM) ended in Jan. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr6.34 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biovica International AB  (OSTO:BIOVIC B) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Biovica International AB's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=1.792/0.133
=13.47

Biovica International AB's share price for today is kr1.792.
Biovica International AB's Revenue per Share for the trailing twelve months (TTM) ended in Jan. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.13.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biovica International AB EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Biovica International AB's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Biovica International AB (OSTO:BIOVIC B) Business Description

Traded in Other Exchanges
Address
Dag Hammarskjolds vag 54B, Uppsala Science Park, Uppsala, SWE, 752 37
Biovica International AB is a biotech company. It develops and commercializes blood-based diagnostic tests with biomarkers that improve monitoring and evaluation of modern cancer treatments. Through collaboration with world- leading cancer institutes and pharmaceutical companies, it promotes the trend in healthcare for personalized treatment, with a primary focus on patient survival and benefits to society. DiviTum is manufactured by the company and sold as a kit consisting of a reaction plate with reagents that have been optimized for ELISA applications.

Biovica International AB (OSTO:BIOVIC B) Headlines

No Headlines